Display options
Cite
Srugo I, Brunell PA, Chelyapov NV, et al. Virus burden in human immunodeficiency virus type 1-infected children: relationship to disease status and effect of antiviral therapy. Pediatrics. 1991;87(6):921-5
Srugo, I., Brunell, P. A., Chelyapov, N. V., Ho, D. D., Alam, M., & Israele, V. (1991). Virus burden in human immunodeficiency virus type 1-infected children: relationship to disease status and effect of antiviral therapy. Pediatrics, 87(6), 921-5.
Srugo, I, et al. "Virus burden in human immunodeficiency virus type 1-infected children: relationship to disease status and effect of antiviral therapy." Pediatrics vol. 87,6 (1991): 921-5.
Srugo I, Brunell PA, Chelyapov NV, Ho DD, Alam M, Israele V. Virus burden in human immunodeficiency virus type 1-infected children: relationship to disease status and effect of antiviral therapy. Pediatrics. 1991 Jun;87(6):921-5. PMID: 2034499.
Copy Download .nbib Format: NLM
Share it on

Pediatrics. 1991 Jun;87(6):921-5.

Virus burden in human immunodeficiency virus type 1-infected children: relationship to disease status and effect of antiviral therapy.

Pediatrics

I Srugo, P A Brunell, N V Chelyapov, D D Ho, M Alam, V Israele

Affiliations

  1. Division of Infectious Diseases, Ahmanson Pediatric Center, Los Angeles, CA 90048.

PMID: 2034499

Abstract

The human immunodeficiency virus type 1 (HIV-1) was isolated from the plasma and peripheral blood mononuclear cells (PBMCs) from each of 21 infected children. The mean titers in plasma were 7 and 165 tissue culture-infective doses per milliliter in 9 children with asymptomatic (P-1) and 12 with symptomatic (P-2) infection, respectively (P = .0013). Significantly higher viral titers were found in PBMCs obtained from P-2 compared with P-1 children: 1920 vs 25 tissue culture-infective doses per 10(6) PBMC (P = .0018). In symptomatic patients at least 1 in 520 circulating mononuclear cells harbored HIV-1. No correlation was found between the viral burden and CD4+ lymphocyte counts. A decrease in the HIV-1 titers was noted both in PBMCs and plasma of symptomatic patients treated with zidovudine for 2 to 7 months. It is concluded that symptomatic children harbor a higher amount of the virus in plasma and PBMCs than asymptomatic children. Zidovudine treatment for 2 months or more decreased the amount of HIV-1 in PBMCs and plasma.

Substances

MeSH terms

Publication Types

Grant support

LinkOut - more resources